AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
Biosynthesis and processing of cathepsin K in cultured human osteoclasts
Authors: Rieman, DJ McClung, HA Dodds, RA Hwang, SM Lark, MW Holmes, S James, IE Drake, FH Gowen, M
Citation: Dj. Rieman et al., Biosynthesis and processing of cathepsin K in cultured human osteoclasts, BONE, 28(3), 2001, pp. 282-289
Clusterin expression in adult human normal and osteoarthritic articular cartilage
Authors: Connor, JR Kumar, S Sathe, G Mooney, J O'Brien, SP Mui, P Murdock, PR Gowen, M Lark, MW
Citation: Jr. Connor et al., Clusterin expression in adult human normal and osteoarthritic articular cartilage, OSTEO CART, 9(8), 2001, pp. 727-737
Identification and initial characterization of 5000 expressed sequenced tags (ESTs) each from adult human normal and osteoarthritic cartilage cDNA libraries
Authors: Kumar, S Connor, JR Dodds, RA Halsey, W Van Horn, M Mao, J Sathe, G Mui, P Agarwal, P Badger, AM Lee, JC Gowen, M Lark, MW
Citation: S. Kumar et al., Identification and initial characterization of 5000 expressed sequenced tags (ESTs) each from adult human normal and osteoarthritic cartilage cDNA libraries, OSTEO CART, 9(7), 2001, pp. 641-653
Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption
Authors: Dodds, RA James, IE Rieman, D Ahern, R Hwang, SM Connor, JR Thompson, SD Veber, DF Drake, FH Holmes, S Lark, MW Gowen, M
Citation: Ra. Dodds et al., Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption, J BONE MIN, 16(3), 2001, pp. 478-486
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat
Authors: Lark, MW Stroup, GB Dodds, RA Kapadia, R Hoffman, SJ Hwang, SM James, IE Lechowska, B Liang, XG Rieman, DJ Salyers, KL Ward, K Smith, BR Miller, WH Huffman, WF Gowen, M
Citation: Mw. Lark et al., Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat, J BONE MIN, 16(2), 2001, pp. 319-327
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate
Authors: Stroup, GB Lark, MW Veber, DF Bhattacharyya, A Blake, S Dare, LC Erhard, KF Hoffman, SJ James, IE Marquis, RW Ru, Y Vasko-Moser, JA Smith, BR Tomaszek, T Gowen, M
Citation: Gb. Stroup et al., Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate, J BONE MIN, 16(10), 2001, pp. 1739-1746
Azepanone-based inhibitors of human and rat cathepsin K
Authors: Marquis, RW Ru, Y LoCastro, SM Zeng, J Yamashita, DS Oh, HJ Erhard, KF Davis, LD Tomaszek, TA Tew, D Salyers, K Proksch, J Ward, K Smith, B Levy, M Cummings, MD Haltiwanger, RC Trescher, G Wang, B Hemling, ME Quinn, CJ Cheng, HY Lin, F Smith, WW Janson, CA Zhao, BG McQueney, MS D'Alessio, K Lee, CP Marzulli, A Dodds, RA Blake, S Hwang, SM James, IE Gress, CJ Bradley, BR Lark, MW Gowen, M Veber, DF
Citation: Rw. Marquis et al., Azepanone-based inhibitors of human and rat cathepsin K, J MED CHEM, 44(9), 2001, pp. 1380-1395
Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro
Authors: James, IE Marquis, RW Blake, SM Hwang, SM Gress, CJ Ru, Y Zembryki, D Yamashita, DS McQueney, MS Tomaszek, TA Oh, HJ Gowen, M Veber, DF Lark, MW
Citation: Ie. James et al., Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro, J BIOL CHEM, 276(15), 2001, pp. 11507-11511
In vitro models for investigation of the effects of acute mechanical injury on cartilage
Authors: Patwari, P Fay, J Cook, MN Badger, AM Kerin, AJ Lark, MW Grodzinsky, AJ
Citation: P. Patwari et al., In vitro models for investigation of the effects of acute mechanical injury on cartilage, CLIN ORTHOP, (391), 2001, pp. S61-S71
Disease-modifying activity of SB 273005, an orally active, nonpeptide alpha(v)beta(3) (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis
Authors: Badger, AM Blake, S Kapadia, R Sarkar, S Levin, J Swift, BA Hoffman, SJ Stroup, GB Miller, WH Gowen, M Lark, MW
Citation: Am. Badger et al., Disease-modifying activity of SB 273005, an orally active, nonpeptide alpha(v)beta(3) (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis, ARTH RHEUM, 44(1), 2001, pp. 128-137
Identification and in vivo efficacy of small-molecule antagonists of integrin or alpha(v)beta(3) (the vitronectin receptor)
Authors: Miller, WH Keenan, RM Willette, RN Lark, MW
Citation: Wh. Miller et al., Identification and in vivo efficacy of small-molecule antagonists of integrin or alpha(v)beta(3) (the vitronectin receptor), DRUG DISC T, 5(9), 2000, pp. 397-408
Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocytecultures
Authors: Badger, AM Roshak, AK Cook, MN Newman-Tarr, TM Swift, BA Carlson, K Connor, JR Lee, JC Gowen, M Lark, MW Kumar, S
Citation: Am. Badger et al., Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocytecultures, OSTEO CART, 8(6), 2000, pp. 434-443
FrzB-2: a human secreted frizzled-related protein with a potential role inchondrocyte apoptosis
Authors: James, IE Kumar, S Barnes, MR Gress, CJ Hand, AT Dodds, RA Connor, JR Bradley, BR Campbell, DA Grabill, SE Williams, K Blake, SM Gowen, M Lark, MW
Citation: Ie. James et al., FrzB-2: a human secreted frizzled-related protein with a potential role inchondrocyte apoptosis, OSTEO CART, 8(6), 2000, pp. 452-463
Meniscal ossification in spontaneous osteoarthritis in the guinea-pig
Authors: Kapadia, RD Badger, AM Levin, JM Swift, B Bhattacharyya, A Dodds, RA Coatney, RW Lark, MW
Citation: Rd. Kapadia et al., Meniscal ossification in spontaneous osteoarthritis in the guinea-pig, OSTEO CART, 8(5), 2000, pp. 374-377
Differential expression of Egr-1 in osteoarthritic compared to normal adult human articular cartilage
Authors: Wang, FL Connor, JR Dodds, RA James, IE Kumar, S Zou, C Lark, MW Gowen, M Nuttall, ME
Citation: Fl. Wang et al., Differential expression of Egr-1 in osteoarthritic compared to normal adult human articular cartilage, OSTEO CART, 8(3), 2000, pp. 161-169
Markers of joint tissue turnover in joint fluids from hips with osteonecrosis of the femoral head
Authors: Jingushi, S Lohmander, LS Shinmei, T Hoerrner, LA Lark, MW Sugioka, Y Iwamoto, Y
Citation: S. Jingushi et al., Markers of joint tissue turnover in joint fluids from hips with osteonecrosis of the femoral head, J ORTHOP R, 18(5), 2000, pp. 728-733
Inhibition of caspase-3-like activity prevents apoptosis while retaining functionality of human chondrocytes in vitro
Authors: Nuttall, ME Nadeau, DP Fisher, PW Wang, F Keller, PM DeWolf, WE Goldring, MB Badger, AM Lee, D Levy, MA Gowen, M Lark, MW
Citation: Me. Nuttall et al., Inhibition of caspase-3-like activity prevents apoptosis while retaining functionality of human chondrocytes in vitro, J ORTHOP R, 18(3), 2000, pp. 356-363
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic
Authors: Miller, WH Alberts, DP Bhatnagar, PK Bondinell, WE Callahan, JF Calvo, RR Cousins, RD Erhard, KF Heerding, DA Keenan, RM Kwon, C Manley, PJ Newlander, KA Ross, ST Samanen, JM Uzinskas, IN Venslavsky, JW Yuan, CCK Haltiwanger, RC Gowen, M Hwang, SM James, IE Lark, MW Rieman, DJ Stroup, GB Azzarano, LM Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF
Citation: Wh. Miller et al., Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic, J MED CHEM, 43(1), 2000, pp. 22-26
CK beta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues
Authors: Votta, BJ White, JR Dodds, RA James, IE Connor, JR Lee-Rykaczewski, E Eichman, CF Kumar, S Lark, MW Gowen, M
Citation: Bj. Votta et al., CK beta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues, J CELL PHYS, 183(2), 2000, pp. 196-207
Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality
Authors: Lee, D Long, SA Adams, JL Chan, G Vaidya, KS Francis, TA Kikly, K Winkler, JD Sung, CM Debouck, C Richardson, S Levy, MA DeWolf, WE Keller, PM Tomaszek, T Head, MS Ryan, MD Haltiwanger, RC Liang, PH Janson, CA McDevitt, PJ Johanson, K Concha, NO Chan, W Abdel-Meguid, SS Badger, AM Lark, MW Nadeau, DP Suva, LJ Gowen, M Nuttall, ME
Citation: D. Lee et al., Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality, J BIOL CHEM, 275(21), 2000, pp. 16007-16014
Injurious mechanical compression of bovine articular cartilage induces chondrocyte apoptosis
Authors: Loening, AM James, IE Levenston, ME Badger, AM Frank, EH Kurz, B Nuttall, ME Hung, HH Blake, SM Grodzinsky, AJ Lark, MW
Citation: Am. Loening et al., Injurious mechanical compression of bovine articular cartilage induces chondrocyte apoptosis, ARCH BIOCH, 381(2), 2000, pp. 205-212
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
Authors: Miller, WH Bondinell, WE Cousins, RD Erhard, KF Jakas, DR Keenan, RM Ku, TW Newlander, KA Ross, ST Haltiwanger, RC Bradbeer, J Drake, FH Gowen, M Hoffman, SJ Hwang, SM James, IE Lark, MW Lechowska, B Rieman, DJ Stroup, GB Vasko-Moser, JA Zembryki, DL Azzarano, LM Adams, PC Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF
Citation: Wh. Miller et al., Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model, BIOORG MED, 9(13), 1999, pp. 1807-1812
Development and characterization of a human in vitro resorption assay: Demonstration of utility using novel antiresorptive agents
Authors: James, IE Lark, MW Zembryki, D Lee-Rykaczewski, EV Hwang, SM Tomaszek, TA Belfiore, P Gowen, M
Citation: Ie. James et al., Development and characterization of a human in vitro resorption assay: Demonstration of utility using novel antiresorptive agents, J BONE MIN, 14(9), 1999, pp. 1562-1569
Down-regulation of chondrocyte aggrecan and type-II collagen gene expression correlates with increases in static compression magnitude and duration
Authors: Ragan, PM Badger, AM Cook, M Chin, VI Gowen, M Grodzinsky, AJ Lark, MW
Citation: Pm. Ragan et al., Down-regulation of chondrocyte aggrecan and type-II collagen gene expression correlates with increases in static compression magnitude and duration, J ORTHOP R, 17(6), 1999, pp. 836-842
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis
Authors: Lark, MW Stroup, GB Hwang, SM James, IE Rieman, DJ Drake, FH Bradbeer, JN Mathur, A Erhard, KF Newlander, KA Ross, ST Salyers, KL Smith, BR Miller, WH Huffman, WF Gowen, M
Citation: Mw. Lark et al., Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis, J PHARM EXP, 291(2), 1999, pp. 612-617
Risultati: 1-25 | 26-28